miRNA-182水平与宫颈癌患者临床病理特征及预后的关系

Relationship between miRNA-182 level and clinicopathological features and prognosis of patients with cervical cancer

摘要

目的 探讨miRNA-182水平与宫颈癌患者临床病理特征及预后的关系。方法 选择2021年2月至2023年6月在海南医学院第一附属医院治疗的112例宫颈癌患者为研究对象,根据研究对象180天随访过程中有无死亡这一不良结局为判断终点,分为预后良好组(78例)和预后不良组(34例).对不同miRNA-182水平患者进行临床特征比较,分析不同miRNA-182水平患者预后情况,研究患者miRNA-182水平与预后不良发生概率的剂量反应关系,进行miRNA-182水平与预后的决策曲线分析(DCA)。结果 与低水平miRNA-182组相比,中高水平组患者年龄较大,吸烟史、糖尿病史、国际妇产科联合会(FIGO)肿瘤分期Ⅲ~Ⅳ期、鳞状细胞癌、辅助治疗给药、淋巴结转移占比较高,饮酒史、阴道浸润占比较低,差异均具有统计学意义(χ²/F值介于3.650~15.118之间,P＜0.05);与预后良好组相比,预后不良组患者miRNA-182水平较高,差异具有统计学意义(t＝2.652,P＜0.05);Cox回归模型显示低、中等水平组患者预后不良风险均低于高水平组(HR值介于0.125~0.566之间,P＜0.05);剂量反应关系结果显示miRNA-182水平与预后不良呈显著正相关性;DCA曲线分析结果显示,高风险阈值在1%~70%内取值越小,净获益率越高,临床意义越大。结论 miRNA-182水平对宫颈癌患者的预后有良好的预测价值,值得临床推广.

Abstract

Objective To investigate the relationship between miRNA-182 levels and the clinical pathological characteristics and prognosis of cervical cancer patients. Methods A total of 112 cervical cancer patients treated at the First Affiliated Hospital of Hainan Medical College from February 2021 to June 2023 were selected as the study subjects, and they were divided into good prognosis group (78 cases) and poor prognosis group (34 cases) according to the adverse outcome of death during the 180-day follow-up of the study subjects. The clinical characteristics of patients with different miRNA-182 levels were compared, the prognosis of patients with different miRNA-182 levels was analyzed, the dose-response relationship between miRNA-182 levels and the probability of adverse prognosis was studied, and the decision curve analysis (DCA) between miRNA-182 levels and prognosis was analyzed. Results Compared with the low-level miRNA-182 group, the patients in the middle-to-high-level group were older, with a higher proportion of smoking history, diabetes history, International Federation of Obstetrics and Gynecology (FIGO) tumor stage Ⅲ-Ⅳ, squamous cell carcinoma, adjuvant therapy administration, lymph node metastasis, alcohol history and vaginal invasion, and the differences were statistically significant (χ ²/F values ranging from 3.650 to 15.118, P＜0.05). Compared with the good prognosis group, the miRNA-182 level was higher in the poor prognosis group, and the difference was statistically significant (t＝2.652, P＜0.05). The Cox regression model showed that the risk of poor prognosis in the low- and middle-level groups was lower than that in the high-level group (HR values ranging from 0.125 to 0.566, P＜0.05). The results of dose-response relationship showed that miRNA-182 level was significantly positively correlated with poor prognosis. The results of DCA curve analysis showed that the smaller the high-risk threshold within 1%~70%, the higher the net benefit rate and the greater the clinical significance. Conclusion The level of miRNA-182 has a good predictive value for the prognosis of cervical cancer patients, which is worthy of clinical promotion.

关键词

miRNA-182 / 宫颈癌 / 临床病理特征 / 预后

Key words

miRNA-182 / cervical cancer / clinicopathological feature / prognosis

参考文献

[1] Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk[J]. Bmj, 2022, 379(1): e070115.

[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[3] Huang L, Liu F, Liu X, et al. Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway[J]. Cancer Chemother Pharmacol, 2024, 93(3): 203-213.

[4] Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative[J]. Lancet Glob Health, 2023, 11(2): e197-e206.

[5] Yi M, Li T, Niu M, et al. Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study[J]. Biomark Res, 2021, 9(1): 55.

[6] 郭凤, 黄伟, 王佩红, 等. miR-944在HPV16阳性宫颈癌患者组织表达及临床意义[J]. 中国妇幼健康研究, 2023, 34(3): 94-98.

[7] Yin S, Cui H, Qin S, et al. Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer[J]. Biomed Pharmacother, 2023, 166(1): 115355.

[8] Hussen B M, Hidayat HJ, Salihi A, et al. MicroRNA: a signature for cancer progression[J]. Biomed Pharmacother, 2021, 138(24): 111528.

[9] Ghafouri-Fard S, Honarmand T K, Hussen B M, et al. MicroRNA signature in liver cancer[J]. Pathol Res Pract, 2021, 219(1): 153369.

[10] Hussen B M, Abdullah ST, Rasul M F, et al. MicroRNAs: important players in breast cancer angiogenesis and therapeutic targets[J]. Front Mol Biosci, 2021, 8(1): 764025.

[11] Hussen B M, Hidayat J, Ghafouri-Fard S. Identification of expression of CCND1-related lncRNAs in breast cancer[J]. Pathol Res Pract, 2022, 236(1): 154009.

[12] Nayak B, Khan N, Garg H, et al. Role of miRNA-182 and miRNA-187 as potential biomarkers in prostate cancer and its correlation with the staging of prostate cancer[J]. Int Braz J Urol, 2020, 46(4): 614-623.

[13] Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2020, 70(5): 321-346.

[14] Alie MS, Negesse Y, Ayenew M. Determinants of cervical cancer screening among women aged 30-49 years old in four african countries: a cross-sectional secondary data analysis[J]. Cancer Control, 2023, 30(4): 107170-427.

[15] 张贤雨, 马欢, 宋凤丽, 等. miR-216a通过下调CAPN6抑制宫颈癌细胞增殖并促进细胞凋亡的研究[J]. 中国妇幼健康研究, 2023, 34(1): 75-84.

[16] Tadesse F, Megerso A, Mohammed E, et al. Cervical cancer screening practice among women: a community based cross-sectional study design[J]. Inquiry, 2023, 60(1): 469580231159743.

[17] Shen S, Zhang S, Liu P, et al. Potential role of microRNAs in the treatment and diagnosis of cervical cancer[J]. Cancer Genet, 2020, 248-249(1): 25-30.

[18] Thapa K, Khan H, Singh TG, et al. Traumatic brain injury: mechanistic insight on pathophysiology and potential therapeutic targets[J]. J Mol Neurosci, 2021, 71(9): 1725-1742.

[19] Shademan B, Zakeri M, Abbasi S, et al. Relationship between miRNA-21, miRNA-155, and miRNA-182 expression and inflammatory factors in cerebrospinal fluid from patients with multiple sclerosis[J]. Clin Neurol Neurosurg, 2023, 232(1): 107873.

[20] Nahand JS, Vandchali N R, Darabi H, et al. Exosomal microRNAs: novel players in cervical cancer[J]. Epigenomics, 2020, 12(18): 1651-1660.

[21] 李芳芳, 陈莉, 张先娟, 等. microRNA-182-5p靶向BNIP3抑制卵巢癌细胞增殖和迁移的研究[J]. 中国临床药理学杂志, 2020, 36(7): 792-795.

[22] Lu X, Li R, Ying Y, et al. Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6A RNA methylation regulators in cervical cancer[J]. J Transl Med, 2022, 20(1): 1-20.

基金资助

海南医学院第一附属医院2020年度青年培育基金(HYYFYPY202004)